JP2014521353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521353A5 JP2014521353A5 JP2014524110A JP2014524110A JP2014521353A5 JP 2014521353 A5 JP2014521353 A5 JP 2014521353A5 JP 2014524110 A JP2014524110 A JP 2014524110A JP 2014524110 A JP2014524110 A JP 2014524110A JP 2014521353 A5 JP2014521353 A5 JP 2014521353A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccinia virus
- present
- culture
- hela cells
- roller bottle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515724P | 2011-08-05 | 2011-08-05 | |
| US61/515,724 | 2011-08-05 | ||
| PCT/US2012/049550 WO2013022764A1 (en) | 2011-08-05 | 2012-08-03 | Methods and compositions for production of vaccina virus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521353A JP2014521353A (ja) | 2014-08-28 |
| JP2014521353A5 true JP2014521353A5 (enExample) | 2016-10-20 |
| JP6243333B2 JP6243333B2 (ja) | 2017-12-06 |
Family
ID=46650950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014524110A Active JP6243333B2 (ja) | 2011-08-05 | 2012-08-03 | ワクシニアウィルスの生成のための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9719105B2 (enExample) |
| EP (1) | EP2739293B1 (enExample) |
| JP (1) | JP6243333B2 (enExample) |
| KR (1) | KR102022952B1 (enExample) |
| CN (1) | CN103732236B (enExample) |
| AU (1) | AU2012294606B2 (enExample) |
| BR (1) | BR112014000787B1 (enExample) |
| CA (1) | CA2841831C (enExample) |
| DK (1) | DK2739293T3 (enExample) |
| ES (1) | ES2813413T3 (enExample) |
| PL (1) | PL2739293T3 (enExample) |
| WO (1) | WO2013022764A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6895374B2 (ja) | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| WO2016128542A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| CA2990133A1 (en) | 2015-06-19 | 2017-03-09 | Sillajen, Inc. | Compositions and methods for viral embolization |
| CN106676071B (zh) * | 2015-11-06 | 2019-07-19 | 天士力创世杰（天津）生物制药有限公司 | HeLa-F细胞及其用途 |
| EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| ES2905478T3 (es) | 2016-12-28 | 2022-04-08 | Transgene Sa | Virus oncolíticos y moléculas terapéuticas |
| JP7718815B2 (ja) | 2017-04-21 | 2025-08-05 | シルラゼン， インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスおよびチェックポイント阻害剤の併用療法 |
| KR102684237B1 (ko) | 2017-06-21 | 2024-07-11 | 트랜스진 | 개인 맞춤형 백신 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| CN113330111A (zh) * | 2018-11-21 | 2021-08-31 | 西方溶瘤细胞有限公司 | 病毒的制造 |
| IL284421B2 (en) | 2018-12-28 | 2025-05-01 | Transgene | M2-defective poxvirus |
| KR102228267B1 (ko) | 2019-01-25 | 2021-03-17 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
| CN112143693B (zh) * | 2019-06-28 | 2024-12-27 | 杭州康万达医药科技有限公司 | 一种生产病毒的方法及收获液组合物 |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| CA3183701A1 (en) * | 2020-06-22 | 2021-12-30 | Sung Jin Kim | Method for large scale-production of vaccinia virus using suspension cells |
| TW202217002A (zh) | 2020-07-13 | 2022-05-01 | 法商傳斯堅公司 | 免疫抑制之治療 |
| WO2022109133A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| WO2022232375A1 (en) | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| CN114395538A (zh) * | 2022-01-19 | 2022-04-26 | 和元生物技术（上海）股份有限公司 | 一种促进重组病毒载体向细胞外分泌的方法 |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| CN119654339A (zh) | 2022-07-01 | 2025-03-18 | 特兰斯吉恩股份有限公司 | 包含表面活性蛋白-d和tnfsf成员的融合蛋白 |
| CN120380015A (zh) | 2022-08-18 | 2025-07-25 | 特兰斯吉恩公司 | 嵌合痘病毒 |
| AU2024236322A1 (en) * | 2023-03-10 | 2025-08-21 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267965B1 (en) * | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| DE20122302U1 (de) * | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| AU2003258168B2 (en) | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| DK1869171T4 (en) * | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| EP1933857A2 (en) * | 2005-09-07 | 2008-06-25 | Jennerex Biotherapeutics ULC | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| JP5326155B2 (ja) * | 2006-08-07 | 2013-10-30 | 一般財団法人化学及血清療法研究所 | 痘瘡生ワクチンの製造方法 |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US8003364B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
| WO2009048769A2 (en) * | 2007-10-10 | 2009-04-16 | Kirin Pharma Kabushiki Kaisha | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| JP2013500717A (ja) | 2009-07-28 | 2013-01-10 | コーニング インコーポレイテッド | 細胞を培養するための合成マイクロキャリア |
| EP2477499B1 (en) * | 2009-09-14 | 2018-04-11 | SillaJen Biotherapeutics, Inc. | Oncolytic vaccinia virus combination cancer therapy |
-
2012
- 2012-08-03 JP JP2014524110A patent/JP6243333B2/ja active Active
- 2012-08-03 AU AU2012294606A patent/AU2012294606B2/en active Active
- 2012-08-03 BR BR112014000787-0A patent/BR112014000787B1/pt active IP Right Grant
- 2012-08-03 WO PCT/US2012/049550 patent/WO2013022764A1/en not_active Ceased
- 2012-08-03 ES ES12746243T patent/ES2813413T3/es active Active
- 2012-08-03 KR KR1020147005901A patent/KR102022952B1/ko active Active
- 2012-08-03 DK DK12746243.0T patent/DK2739293T3/da active
- 2012-08-03 CA CA2841831A patent/CA2841831C/en active Active
- 2012-08-03 CN CN201280038029.8A patent/CN103732236B/zh active Active
- 2012-08-03 EP EP12746243.0A patent/EP2739293B1/en active Active
- 2012-08-03 PL PL12746243T patent/PL2739293T3/pl unknown
- 2012-08-03 US US14/236,982 patent/US9719105B2/en active Active
-
2017
- 2017-06-27 US US15/634,765 patent/US10202581B2/en active Active
-
2019
- 2019-02-07 US US16/270,585 patent/US10767166B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521353A5 (enExample) | ||
| US8778675B2 (en) | Immortalized avian cell lines and use thereof | |
| JP6243333B2 (ja) | ワクシニアウィルスの生成のための方法および組成物 | |
| JP2012507270A5 (enExample) | ||
| JP2016105737A5 (enExample) | ||
| JP2004501647A5 (enExample) | ||
| WO2020076820A3 (en) | Compositions and methods for preparing viral vectors | |
| JP2009528843A5 (enExample) | ||
| JP2013507935A5 (enExample) | ||
| CN104087613B (zh) | 基于aav‑itr的基因表达微载体及其构建方法和应用 | |
| JP2025169249A5 (enExample) | ||
| CN111484972A (zh) | 一种从儿童包皮培养获得具备多向分化潜能和免疫调节功能间充质干细胞的方法 | |
| CN111218477A (zh) | 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用 | |
| Galante et al. | Identification and characterization of Orf viruses isolated from sheep and goats in Southern Italy | |
| Bratt et al. | Genetics and paragenetic phenomena of paramyxoviruses | |
| CN113583980A (zh) | 一种猪繁殖与呼吸综合征突变病毒及其构建方法与应用 | |
| WO2006038742A1 (ja) | 組み換えウイルスおよびその用途 | |
| CN118581115A (zh) | 一种猪丁型冠状病毒感染性cDNA克隆及构建方法和应用 | |
| Pelz et al. | Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus | |
| CN111662883A (zh) | 一种制备及纯化溶瘤病毒的方法及重组溶瘤弹状病毒 | |
| Slovic et al. | Genetic variability and sequence relatedness of matrix protein in viruses of the families paramyxoviridae and pneumoviridae | |
| Saghi et al. | Biochemical characterization of temperature-sensitive rabies virus mutants | |
| CN104774873A (zh) | 一种体外组装草鱼呼肠孤病毒制备方法 | |
| JPWO2023066874A5 (enExample) | ||
| CN116162599B (zh) | GSK3β在增强塞内卡病毒复制用于制备疫苗中的用途 |